News & Updates

Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.

Twice-daily application of the botanical coacillium 22.25% cutaneous solution leads to significant hair growth in children and adolescents with moderate-to-severe alopecia areata (AA), with the improvement in hair loss sustained through months after treatment discontinuation, according to data from the phase II/III RAAINBOW trial.

The experimental drug amlitelimab has scored positive outcomes in the double-blind, placebo-controlled phase IIb STREAM-AD study evaluating it as a treatment for moderate-to-severe atopic dermatitis (AD).

In children and adults with moderate-to-severe atopic dermatitis, applying tapinarof cream 1% helps reduce itch within 24 hours, according to the results of the phase III trials ADORING 1 and 2.

In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.

A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

In the phase III ARCADIA 1 and 2 trials, the investigational, first-in-class interleukin-31-Rα antagonist nemolizumab delivered early, rapid, and sustained improvements in the core signs and symptoms of atopic dermatitis (AD) in patients with moderate-to-severe disease.

Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.